RGEN

Repligen Corporation (RGEN)

Healthcare • Medical Instruments & Supplies

StockNasdaqGSUnited StatesUS7599161095

166.68 USD +0.10% today Updated 13 Nov 2026 14:35

Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Repligen Corporation, and has no access to any account you may have with it. The name and the logo belong to their owners.

Price history

Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.

All time

Updated 13 Nov 2026 14:35. Information, not advice. Showing the last 12 months. Create a free account to see the whole history

Results

Next results 23 Feb 2027 in 102 days · 08:00 · estimate 0.52

Last results 0.53 vs 0.46 estimated 27 Oct 2026 · Beat +14.5%

Beat the estimate 9 of 12 3 missed · 0 in line · 5 beats in a row

Average surprise +9.5% reported against the estimate, last 12 quarters

Earnings per share: estimate and reported

Estimate Reported: beat Reported: miss In line

Quarterly results

Date	EPS estimate	EPS reported	Surprise	Result
23 Feb 2027 08:00	0.52	—	—	Upcoming
27 Oct 2026 07:00	0.46	0.53	+14.5%	Beat
28 Jul 2026 07:00	0.45	0.54	+20.4%	Beat
05 May 2026 07:00	0.39	0.48	+22.9%	Beat
24 Feb 2026 07:00	0.44	0.49	+10.4%	Beat
28 Oct 2025 07:00	0.42	0.46	+10.6%	Beat
29 Jul 2025 07:00	0.39	0.37	-5.0%	Miss
29 Apr 2025 07:00	0.35	0.39	+11.5%	Beat
20 Feb 2025 07:00	0.41	0.44	+7.9%	Beat
12 Nov 2024 07:00	0.33	0.43	+29.4%	Beat
30 Jul 2024 07:00	0.33	0.33	+1.4%	Beat
01 May 2024 07:00	0.30	0.28	-7.0%	Miss
21 Feb 2024 07:00	0.34	0.33	-2.6%	Miss
31 Oct 2023 07:00	0.16	0.23	+39.5%	Beat
02 Aug 2023 07:00	0.48	0.53	+11.6%	Beat
02 May 2023 07:00	0.59	0.64	+8.8%	Beat
22 Feb 2023 07:00	0.58	0.68	+18.0%	Beat
01 Nov 2022 07:00	0.68	0.77	+13.2%	Beat
02 Aug 2022 07:00	0.71	0.91	+27.4%	Beat
27 Apr 2022 07:00	0.72	0.92	+27.7%	Beat
17 Feb 2022 07:00	0.65	0.81	+24.9%	Beat
28 Oct 2021 07:00	0.64	0.78	+22.5%	Beat
27 Jul 2021 07:00	0.52	0.79	+50.8%	Beat
04 May 2021 07:00	0.42	0.68	+61.0%	Beat
24 Feb 2021 07:00	0.31	0.52	+69.9%	Beat
05 Nov 2020 07:00	0.28	0.40	+45.0%	Beat
30 Jul 2020 07:00	0.28	0.42	+51.3%	Beat
06 May 2020 08:00	0.22	0.32	+43.7%	Beat
20 Feb 2020 07:00	0.18	0.20	+8.1%	Beat
31 Oct 2019 07:00	0.19	0.26	+35.1%	Beat
01 Aug 2019 07:00	0.30	0.31	+3.3%	Beat
09 May 2019 07:00	0.22	0.28	+29.2%	Beat
21 Feb 2019 07:00	0.21	0.21	+2.1%	Beat
01 Nov 2018 07:00	0.18	0.20	+13.2%	Beat
02 Aug 2018 07:00	0.18	0.16	-10.2%	Miss
08 May 2018 07:00	0.15	0.17	+15.2%	Beat
22 Feb 2018 07:00	0.12	0.20	+61.9%	Beat
09 Nov 2017 07:00	0.11	0.15	+34.3%	Beat
03 Aug 2017 07:00	0.15	0.20	+33.9%	Beat
04 May 2017 07:00	0.13	0.15	+19.1%	Beat
22 Feb 2017 07:00	0.07	0.08	+14.3%	Beat
03 Nov 2016 07:00	0.08	0.08	0.0%	In line
04 Aug 2016 07:00	0.13	0.16	+28.0%	Beat
05 May 2016 07:00	0.13	0.12	-7.7%	Miss
25 Feb 2016 07:00	0.07	0.07	0.0%	In line
05 Nov 2015 07:00	0.07	0.08	+14.4%	Beat
06 Aug 2015 07:00	0.09	0.11	+29.4%	Beat
07 May 2015 07:00	0.07	0.09	+28.6%	Beat
13 Mar 2015 07:00	0.04	0.05	+26.4%	Beat
06 Nov 2014 07:00	0.04	0.04	+26.3%	Beat

Annual results · USD

Year	Revenue	Change	Net income	Net margin	EPS	EPS change	Free cash flow
2025	738.3M	+16.4%	48.9M	6.6%	0.86	+287.0%	91.7M
2024	634.4M	+0.3%	-25.5M	-4.0%	-0.46	-162.2%	142.5M
2023	632.4M	-21.1%	35.6M	5.6%	0.74	-77.2%	74.9M
2022	801.5M	—	186M	23.2%	3.24	—	38.7M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Day Week Month

Price history in USD, by week
Period	Opening price	High	Low	Closing price	Change	Volume
09 Nov 2026 – 13 Nov 2026 In progress	174.29	181.02	163.85	166.68	-3.93%	3,596,299
02 Nov 2026 – 06 Nov 2026	178.12	188.50	168.03	173.49	-1.95%	6,056,300
26 Oct 2026 – 30 Oct 2026	176.93	191.05	164.88	176.94	+0.01%	10,102,500
19 Oct 2026 – 23 Oct 2026	177.82	185.03	172.00	176.93	+0.86%	4,889,300
12 Oct 2026 – 16 Oct 2026	171.73	186.00	169.73	175.42	+0.89%	5,632,200
05 Oct 2026 – 09 Oct 2026	178.75	194.36	157.44	173.88	-4.30%	8,514,900
28 Sep 2026 – 02 Oct 2026	187.25	198.87	177.12	181.70	-4.21%	6,842,700
21 Sep 2026 – 25 Sep 2026	176.89	192.49	176.22	189.68	+7.23%	6,057,200
14 Sep 2026 – 18 Sep 2026	166.74	179.10	162.10	176.89	+7.09%	4,679,400
08 Sep 2026 – 11 Sep 2026	168.05	172.95	161.14	165.18	-1.44%	3,761,100
00 Mon 0000	157.29	236.48	315.67	394.86	+0.00%	000,000
00 Mon 0000	553.24	632.43	711.62	790.81	+0.00%	000,000
00 Mon 0000	49.19	128.38	207.57	286.76	+0.00%	000,000
252 older periods: create a free account to see the whole history

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Repligen: 3 Key Takeaways for Long-Term Investors (opens in a new tab) Motley Fool · 05 Nov 2026 16:50
Repligen Corporation to Present at Jefferies Global Healthcare Conference (opens in a new tab) 04 Nov 2026 12:00
RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook (opens in a new tab) StockStory · 01 Nov 2026 02:19
5 must-read analyst questions from Repligen’s Q3 earnings call (opens in a new tab) StockStory · 31 Oct 2026 14:35
Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook (opens in a new tab) Insider Monkey · 28 Oct 2026 15:09
Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings (opens in a new tab) Insider Monkey · 28 Oct 2026 14:14
Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance (opens in a new tab) Simply Wall St. · 28 Oct 2026 01:10
Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN) (opens in a new tab) Simply Wall St. · 27 Oct 2026 21:06
Repligen (RGEN) Takes $41.2 Million Impairment Charge As Quarterly Profit Turns To Loss (opens in a new tab) Simply Wall St. · 27 Oct 2026 20:14
Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Is Priced In (opens in a new tab) Simply Wall St. · 27 Oct 2026 18:07
Repligen Corporation Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 27 Oct 2026 17:11
Repligen (RGEN) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 27 Oct 2026 15:59
What Repligen (RGEN) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 27 Oct 2026 15:05
Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations (opens in a new tab) StockStory · 27 Oct 2026 11:44
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates (opens in a new tab) Zacks · 27 Oct 2026 11:15

Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close: 166.52 USD
Market cap: 10.6B
Exchange: NasdaqGS
Country: United States
Sector: Healthcare
Industry: Medical Instruments & Supplies
Currency: USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the score	Points	Why
Business growth Yearly growth of revenue and of earnings per share.	0.0 / 25	Revenue growth of -2.7% a year Earnings per share growth of -35.7% a year
Quality Return on equity, net margin and how stable the margins are.	0.0 / 25	ROE of -1%
Financial strength Net debt against operating earnings, interest cover and free cash flow.	11.6 / 20	Net debt is -1.2× EBITDA Free cash flow yield of 1.0%
Valuation Free cash flow yield and the P/E against its sector.	1.3 / 15	Forward P/E 62.8: it is expected to earn money
Analysts How far the analysts' average target is from today's price.	10.0 / 10	Analysts' target is +22% from the price

Thin interest cover: operating profit is only 1.9× the interest

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works

Figures

Valuation
Figure	Value	Reading	Sector median
P/E (forward)	62.79×	Weak	14.16×
Price / book	4.51×	Weak	3.5×
Price / sales	13.21×	Weak	3.33×
EV / EBITDA	72.99×	Weak	11.19×
Free cash flow yield	1%	Weak	2.1%

Quality
Figure	Value	Reading	Sector median
Gross margin	53.8%	Good	54.9%
Operating margin	8.1%	Fair	5.8%
Net margin	-1.5%	Weak	1.2%
Return on equity	-0.6%	Weak	4.4%
Return on assets	1.4%	Weak	2.7%

Growth
Figure	Value	Reading	Sector median
Revenue growth / year	-2.7%	Weak	10.1%
EPS growth / year	-35.7%	Weak	10.2%

Financial health
Figure	Value	Reading	Sector median
Debt / equity	0.33×	Good	0.4×
Net debt / EBITDA	-1.19×	Good	1.46×
Interest cover	1.93×	Weak	2.17×
Current ratio	9.88×	Good	2.64×

Dividends
Figure	Value	Reading	Sector median
Payout of earnings	0%	Weak	0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Similar shares

Follow RGEN and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in